130 related articles for article (PubMed ID: 26588708)
1. A novel role for atypical MAPK kinase ERK3 in regulating breast cancer cell morphology and migration.
Al-Mahdi R; Babteen N; Thillai K; Holt M; Johansen B; Wetting HL; Seternes OM; Wells CM
Cell Adh Migr; 2015; 9(6):483-94. PubMed ID: 26588708
[TBL] [Abstract][Full Text] [Related]
2. ERK3 is involved in regulating cardiac fibroblast function.
Sahadevan P; Dingar D; Nawaito SA; Nair RS; Trépanier J; Sahmi F; Shi Y; Gillis MA; Sirois MG; Meloche S; Tardif JC; Allen BG
Physiol Rep; 2024 Jun; 12(11):e16108. PubMed ID: 38872461
[TBL] [Abstract][Full Text] [Related]
3. The atypical mitogen-activated protein kinase ERK3 is essential for establishment of epithelial architecture.
Takahashi C; Miyatake K; Kusakabe M; Nishida E
J Biol Chem; 2018 Jun; 293(22):8342-8361. PubMed ID: 29674317
[TBL] [Abstract][Full Text] [Related]
4. Phosphoproteomic analysis identifies supervillin as an ERK3 substrate regulating cytokinesis and cell ploidy.
Javary J; Goupil E; Soulez M; Kanshin E; Bouchard A; Seternes OM; Thibault P; Labbé JC; Meloche S
J Cell Physiol; 2024 Mar; 239(3):e30938. PubMed ID: 36576983
[TBL] [Abstract][Full Text] [Related]
5. Crystal Structure and Inhibitor Identifications Reveal Targeting Opportunity for the Atypical MAPK Kinase ERK3.
Schröder M; Filippakopoulos P; Schwalm MP; Ferrer CA; Drewry DH; Knapp S; Chaikuad A
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114754
[TBL] [Abstract][Full Text] [Related]
6. The non-classical MAP kinase ERK3 controls T cell activation.
Marquis M; Boulet S; Mathien S; Rousseau J; Thébault P; Daudelin JF; Rooney J; Turgeon B; Beauchamp C; Meloche S; Labrecque N
PLoS One; 2014; 9(1):e86681. PubMed ID: 24475167
[TBL] [Abstract][Full Text] [Related]
7. ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells.
Bian K; Muppani NR; Elkhadragy L; Wang W; Zhang C; Chen T; Jung S; Seternes OM; Long W
Oncotarget; 2016 Feb; 7(6):6665-75. PubMed ID: 26701725
[TBL] [Abstract][Full Text] [Related]
8. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Harvey V; Neven P; Arnould L; Maibach R; Price KN; Coates AS; Goldhirsch A; Gelber RD; Pagani O; Viale G; Rae JM; Regan MM;
Breast Cancer Res Treat; 2015 Dec; 154(3):543-55. PubMed ID: 26590813
[TBL] [Abstract][Full Text] [Related]
9. PAK4 promotes kinase-independent stabilization of RhoU to modulate cell adhesion.
Dart AE; Box GM; Court W; Gale ME; Brown JP; Pinder SE; Eccles SA; Wells CM
J Cell Biol; 2015 Nov; 211(4):863-79. PubMed ID: 26598620
[TBL] [Abstract][Full Text] [Related]
10. L290P/V mutations increase ERK3's cytoplasmic localization and migration/invasion-promoting capability in cancer cells.
Alsaran H; Elkhadragy L; Shakya A; Long W
Sci Rep; 2017 Nov; 7(1):14979. PubMed ID: 29101390
[TBL] [Abstract][Full Text] [Related]
11. New insights into the activation, interaction partners and possible functions of MK5/PRAK.
Perander M; Keyse SM; Seternes OM
Front Biosci (Landmark Ed); 2016 Jan; 21(2):374-84. PubMed ID: 26709779
[TBL] [Abstract][Full Text] [Related]
12. Substrate-Dependent Activity of ERK and MEK Proteins in Breast Cancer (MCF7), and Kidney Embryonic (Hek-293) Cell Lines, Cultured on Different Substrates.
Taherian A; Haas TA; Davoodabadi A
Iran J Cancer Prev; 2015 Oct; 8(5):e3909. PubMed ID: 26634110
[TBL] [Abstract][Full Text] [Related]
13. LncMAPK6 drives MAPK6 expression and liver TIC self-renewal.
Huang G; Jiang H; He Y; Lin Y; Xia W; Luo Y; Liang M; Shi B; Zhou X; Jian Z
J Exp Clin Cancer Res; 2018 May; 37(1):105. PubMed ID: 29764463
[TBL] [Abstract][Full Text] [Related]
14. Role of the Atypical MAPK ERK3 in Cancer Growth and Progression.
Elkhadragy L; Myers A; Long W
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611058
[TBL] [Abstract][Full Text] [Related]
15. ERK3 Increases Snail Protein Stability by Inhibiting FBXO11-Mediated Snail Ubiquitination.
Kim SH; Ryu KJ; Hong KS; Kim H; Han H; Kim M; Kim T; Ok DW; Yang JW; Hwangbo C; Kim KD; Yoo J
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201533
[TBL] [Abstract][Full Text] [Related]
16. ERK3 and DGKζ interact to modulate cell motility in lung cancer cells.
Myers AK; Morel M; Gee SH; Hoffmann KA; Long W
Front Cell Dev Biol; 2023; 11():1192221. PubMed ID: 37287450
[TBL] [Abstract][Full Text] [Related]
17. ERK3/MAPK6 dictates CDC42/RAC1 activity and ARP2/3-dependent actin polymerization.
Bogucka-Janczi K; Harms G; Coissieux MM; Bentires-Alj M; Thiede B; Rajalingam K
Elife; 2023 Apr; 12():. PubMed ID: 37057894
[TBL] [Abstract][Full Text] [Related]
18. CircDNAJC11 interacts with TAF15 to promote breast cancer progression via enhancing MAPK6 expression and activating the MAPK signaling pathway.
Wang B; Chen H; Deng Y; Chen H; Xing L; Guo Y; Wang M; Chen J
J Transl Med; 2023 Mar; 21(1):186. PubMed ID: 36895010
[TBL] [Abstract][Full Text] [Related]
19. The TLK1-MK5 Axis Regulates Motility, Invasion, and Metastasis of Prostate Cancer Cells.
Khalil MI; De Benedetti A
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497211
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
